ResearcherDankook UniversityActive in the last 2 years
Hong-Quan Duong
Matched on ORCID iD 0000-0003-1793-9826; OpenAlex author ID A5019799355.
Their work
- Papers
- 8 (first author 8, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 7
2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 8
- Aldehyde Dehydrogenase-1A1 (ALDH1A1): The Novel Regulator of Chemoresistance in Pancreatic Cancer Cells. First author DOI 10.1177/10732748241305835↗
- Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. First author DOI 10.3892/or.2021.7979↗
- Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. First author DOI 10.3390/antiox6030052↗
- Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. First author DOI 10.3892/ijo.2013.2229↗
- Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. First author DOI 10.3892/ijo.2014.2357↗
- Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. First author DOI 10.1111/jcmm.12101↗
- Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. First author DOI 10.3892/ijo.2012.1516↗
- BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. First author DOI 10.3892/ijo.2012.1672↗
Closest collaborators
The 7 strongest of 7 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Yeon-Sun Seong · 7 shared papers, 2012–2021
- Paper Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. DOI 10.3892/or.2021.7979↗
- Paper Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. DOI 10.3390/antiox6030052↗
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- The-Hung Dang · 2 shared papers, 2021–2024
- Insoo Bae · 5 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. DOI 10.3892/ijo.2012.1672↗
- Yong Weon Yi · 3 shared papers, 2013–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. DOI 10.1111/jcmm.12101↗
- Seunghoon Oh · 1 shared paper, 2017
- Young Bin Hong · 2 shared papers, 2013–2014
- Yeon Jeong Kim · 1 shared paper, 2013
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.